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ABSTRACT
Background. Two randomized intraoperative radiation
therapy trials for early-stage breast cancer were recently
published. The ELIOT Trial used electrons (IOERT), and
the TARGIT-A Trial Update used 50-kV X-rays (IORT).
These studies were compared for similarities and differ-
ences. The results were analyzed and used to determine
which patients might be suitable for single-dose treatment.
Methods. The primary sources of data were the ELIOT Trial
and TARGIT-A Trial, as well as a comprehensive analysis of
the peer-reviewed literature of accelerated partial breast irra-
diation (APBI) using 50-kV X-rays or electrons. Studies
published or presented prior to March 2014 were analyzed for
efficacy, patient restrictions, complications, and outcome.
Results. With a median follow-up of 5.8 years, the 5-year
recurrence rates for ELIOT versus EBRT patients were 4.4
and 0.4 %, respectively, p = 0.0001. A low-risk ELIOT
group was identified with a 5-year recurrence rate of 1.5 %.
With a median follow-up of 29 months, the 5-year recur-
rence rates for the TARGIT-A versus EBRT patients were
3.3 and 1.3 %, respectively, p = 0.042.
Conclusions. With 5.8 years of median follow-up, IOERT
appears to have a subset of low risk women for whom
IOERT is acceptable. With 29 months of median follow-up
the results of IORT with 50-kV devices are promising, but
longer follow-up data are required. At the current time,
single-fraction IOERT or IORT patients should be treated
under strict institutional protocols.
In the preceding report (Part 1) in this issue of the
Annals, we outline the rationale for intraoperative radiation
therapy (IORT) and begin a critical analysis of the 2 pro-
spective randomized trials currently published. Part 1
discusses the ELIOT Trial, a trial using electrons during
surgery as the entire radiation therapy treatment. In this
report, we continue with a critical analysis of the TARGIT-
A Trial, a trial that used 50-kV x-rays rather than electrons.
METHODS
See Part I for methods used in the analysis.
TARGIT-A Trial
Overview The TARGIT-A Trial randomized 3,451
patients either to standard EBRT treatment or to
TARGIT-A. Eligibility criteria were age C 45 years,
tumor size B 3.5 cm, N0–1, M0, and unifocal invasive
ductal carcinoma. If the participating institution
determined the patient was at high risk for recurrence, an
additional 5 weeks of EBRT was given, calling this ‘‘risk-
adapted IORT.’’ The Trial began in March 2000.
Beginning in 2004, approximately 30 % of the patients
had TARGIT-A after final pathology in a second surgical
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procedure about 30 days after the original surgery. This
group was designated the ‘‘postpathology’’ group as
opposed to the ‘‘prepathology’’ group who received
TARGIT-A during initial tumor surgery. The results for
these different patient cohorts are shown in Table 1.
Technique In the prepathology TARGIT-A patients,
following tumor excision, an appropriately sized
spherical applicator was placed in the tumor bed. Purse
string sutures were used to approximate breast tissue at risk
to the applicator. Radiation was delivered over 20–45 min
to the tumor bed, which received 20 Gy at the surface of
the applicator and attenuated to 5–7 Gy at 1-cm depth. If
risk factors were found at the time of surgery or
postoperatively, when final pathology was available, the
20 Gy TARGIT treatment was considered as a boost, and
patients received an additional 50 Gy equivalent of EBRT,
delivered over 3–5 weeks, depending on the institutional
preference. Institutions were free to determine what risk
factors required additional EBRT.
The postpathology TARGIT-A patients received
20 Gy irradiation after final pathology determined no risk
Ipsilateral Breast Recurrence
Prepathology, Local Recurrence
Overall Breast Recurrence, All
(b) Overall breast cancer recurrence, p=0.053 (Iipsilateral, 
contralateral, axilla and distant) Presented at SABCS, but not in 
Lancet 2013
(a) IBTR, 3.3% Targit, 1.3% EBRT, p=0.042
(c) IBTR, pre-pathology
2.1% Targit, 1.1% EBRT, p=0.31
Postpathology, Local Recurrence
(d) IBTR, post-pathology
5.4% Targit, 1.7% EBRT, p=0.069
FIG. 1 5-year Kaplan–Meier projections for recurrences from
TARGIT-A treated patients vs EBRT treated patients. a Ipsilateral
breast recurrence. b Overall breast recurrence. c Prepathology, local
recurrence. d Postpathology, local recurrence. Adapted from Figs. 2
and 3 in Lancet7
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factors, typically within 30 days of surgical tumor
removal.
The EBRT patients, whether prepathology or postpa-
thology, received 3–5 weeks of 50 Gy equivalent
EBRT ± boost depending on the institutional preference.
Complications Wound complications were similar
between groups, but grade 3 or 4 skin complications
were significantly reduced with TARGIT (4 of 1720) vs
EBRT (13 of 1731), p = 0.029.
Regional Failures Regional failures were similar in both
groups (8 events for TARGIT vs 6 events for EBRT) (p = 0.6).
Results At 29 months of median follow-up, the 5-year
risk of local recurrence was 1.3 % for EBRT and 3.3 % for
all TARGIT-A patients (p = 0.042). Target A
prepathology patients had a 5-year risk of 2.1 %.
Postpathology patients had a 5-year risk of 5.7 %.
Overall recurrence (ipsilateral breast, contralateral
breast, axilla, and distant) showed a worsening trend for
TARGIT A compared with EBRT: 69 events vs 48 events
(p = 0.053). Both postpathology and prepathology TAR-
GIT-A patients had more local recurrences than the EBRT
patients, although the difference was not statistically sig-
nificant. Postpathology patients exceeded the Trial’s preset
noninferiority margin of 2.5 % (5.4 vs 1.7 %, p = 0.069);
prepathology patients did not (2.1 vs 1.0 %, p = 0.31).
Approximately 21 % of prepathology patients who
received TARGIT-A also had 5 weeks of EBRT because of
risk factors determined at the time of surgery or when final
histopathology was available. Patients who received only
TARGIT-A had 3 times the recurrence rate of those who
received TARGIT-A plus 5 weeks of EBRT (2.7 vs 0.9 %).
This difference was not significant, but no p value was
provided. Ipsilateral breast recurrence rates for all patients,
for prepathology and postpathology patients, and for any
breast recurrence are shown in Fig. 1.
Survival Breast cancer mortality was similar for
TARGIT (2.6 %) vs EBRT (1.9 %), p = 0.56. TARGIT
resulted in significantly fewer non-breast-cancer deaths
1.4 % (n = 17) vs 3.5 % (n = 35), p = 0.0086. This was
due to fewer deaths from cardiovascular causes and other
cancers. Overall mortality was 3.9 % for TARGIT versus
5.3 % for EBRT, p = 0.099.
DISCUSSION
Between March 2000 and April 2010 2,232 patients were
accrued, sufficient for proof of noninferiority.1 Results were
reported 3 months after completion of accrual when the
median follow-up was 25 months.1 The authors maintained
early publication was justified because proof of noninferi-
ority required only 585 patients, and they had reached that
number with a 4.6-year median follow-up. Also they said
peak recurrences for breast cancer occur in years 2 and 3,
offering in support that no recurrences were seen in year 4.
At that time, critics expressed concern mainly about the
immaturity of the data.2–6 Accrual and randomization of
1,219 additional patients continued until June 2012,
increasing the Trial population to 3,451 patients, resulting
in a median follow-up of just 29 months.7
The TARGIT-A update shows recurrences in both the
TARGIT and EBRT groups in year 4.
At the time of the update, the 5 EBRT recurrences ini-
tially reported more than doubled to 11, and the six initial
TARGIT recurrences had almost quadrupled to 23, ques-
tioning the claim of a recurrence peak at 2 or 3 years.1,7
The results of the TARGIT-A trial, with a median follow-
up (FU) of 29 months, is still well below the median time
when breast recurrences can be expected, especially since
more than 90 % of TARGIT-A women were estrogen
receptor positive, and at least 65 % received adjuvant
hormonal therapy, a treatment well-known to delay recur-
rences in ER ? women.1,7–9
The authors used binomial proportion statistics to show
equivalence between the mature cohort (2,232 patients,
median FU = 3 years, 7 months), the earliest cohort
(1,222 patients, median FU = 5 years), and the total cohort
(3,451 patients, median FU = 2 years 5 months). Haviland
points out that binomial proportion statistics is invalid for
follow-ups less than 5 years and that the appropriate sta-
tistical methodology is survival analysis for local
recurrence.10 Only 18 % of patients had a FU of 5 years in
the TARGIT-A update.7 Haviland estimates the hazard
ratio for the reported local recurrence rates and calculates
the local recurrence rate for TARGIT-A could be as high as





Prepathology Targit 10 2.1 % 0.31
Prepathology EBRT 6 1.1 %
Postpathology Targit 13 5.4 % 0.069
Postpathology EBRT 5 1.7 %
Prepathology Targit alone
(N = 793)
*7a 2.7 % Not
stated
Prepathology Targit ? boost
(N = 219)
*3a 0.9 %
Reprinted with permission of Springer Science & Business Media24
a Number of recurrences extrapolated from presented data
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7.1 %, far exceeding the noninferiority margin of 2.5 %
established by the trial.
The initial TARGIT-A publication did not differentiate
between prepathology and postpathology patients or Targit
boost patients.1 The TARGIT update shows these strata are
not equivalent, with postpathology having higher local
recurrence rates than prepathology (Table 2), despite
postpathology patients presumably being lower risk as the
treatment was delivered in a second operation after final
pathology.7 The authors attribute the difference either to
delay in wound fluid suppression of tumor cells, since there
is a delay of radiation in postpathology TARGIT, or to a
geometric miss when inserting the applicator postsurgery.
While geometric miss might partially explain the results, it
is not the likely a major cause of their findings. The IORT
Intrabeam boost study of 299 patients reported no differ-
ence in recurrence rates between prepathology and
postpathology patients.11 The 5-year recurrence rate for all
patients was 1.73 %. The authors do not report the median
applicator size used in the prepathology and postpathology
patients, but if the median sizes reported in other Intrabeam
publications are used, it is likely that postpathology
patients had irradiated tissue volumes less than half the
volumes in prepathology patients.11,12 In IORT boost,
EBRT can compensate for the smaller volume irradiated in
the postpathology patients. One can also see this trend in
the prepathology TARGIT patients since TARGIT plus
EBRT has three times fewer local recurrences than TAR-
GIT alone even though those who also received 5 weeks of
EBRT were presumably at higher risk (Table 2).
The authors note that the difference in IBTR for all
patients is still within their absolute noninferiority margin
of 2.5 % (Fig. 1a).7 Cuzick cautions that the authors have
misused the noninferiority criterion, which requires the
upper confidence interval (CI) be less than the predefined
noninferiority level of 2.5 %.13 In the TARGIT-A update,
the upper CI was 5.1 %, throwing doubt on their assertion
of noninferiority.7 Looking at the divergence of slopes in
Fig. 1a, it appears likely that the 2.5 % noninferiority cri-
terion for IBTR will be exceeded irrespective of the CI
upper limit.
Overall breast recurrence rates in the TARGIT group
also exceeded rates in the EBRT group (Fig. 1b), a dif-
ference at borderline statistical significance (p = 0.053).14
While the difference in breast cancer deaths with TARGIT
vs EBRT is not significant (20 deaths, 2.6 % vs. 16 deaths,
1.9 %, p = 0.56), these higher recurrence rates with short
follow-up suggests more follow-up is needed.
Follow-up may also be too short to determine whether
prepathology TARGIT patients will ultimately do better
than the entire TARGIT cohort. The difference between
this favorable TARGIT cohort and the EBRT group is
1.0 %, with a median follow-up of 29 months, compared
with a difference of .25 % between the TARGIT group and
the EBRT group in the initial publication.1, 7
The TARGIT study involved 33 centers in 11 countries and
lasted more than 12 years. A large multi-institutional study
such as TARGIT-A demands a high level of control and
standardization. However, in TARGIT-A, each center treated
the EBRT group according to its own institutional guidelines
and could determine its own criteria for which patients would
receive TARGIT boost rather than TARGIT APBI.
Sperk et al. analyzed recurrences in the Mannheim
cohort of TARGIT-A patients.15 Among 54 TARGIT-A
patients, 37 % were converted from TARGIT APBI to
TARGIT Boost because of risk factors Sperk et al. chose
for conversion, which included larger tumors ([2 cm) with
narrower margins (\10 mm). With a median follow-up of
40 months, they report no recurrences in the 34 patients
who received TARGIT APBI. Notably, 80 % of their
patients also received adjuvant endocrine therapy, which
could delay the appearance of recurrences. Nevertheless, if
these good results are sustained with longer follow-up and
can be replicated by other centers, it is possible that T1
tumors and wide excision surgery with adjuvant endocrine
therapy could form a basis for ‘‘risk-adapted’’ TARGIT
treatment. The variability of standards from center to
center in the TARGIT-A Trial makes it more difficult to
identify which cohort of women might benefit from this
treatment strategy.
Prepathology women meeting the general TARGIT-A
inclusion criteria appear to be the best candidates. How-
ever, at least 20 % of women who receive TARGIT
treatment will also require 5 weeks of EBRT. Because the
TARGIT-A study allowed treatment centers to determine
the risk factors that required an additional 5 weeks of
treatment, the Trial provides no guidance to new adopters
as to when it is appropriate to add additional treatment.
The volume of tissue irradiated with the TARGIT
technique is of concern because dose decreases rapidly
with distance from the applicator surface. Even assuming
favorable radiobiological equivalence, only tissue within a
few mm of the applicator surface receives as much as a
50-Gy EBRT equivalent dose.
In the Milan III Trial, quandrantectomy alone was
insufficient to achieve local control in early-stage breast
cancer, even though 20 mm of tissue beyond the tumor was
excised in all directions.16 At 10 years, local recurrence
rates in patients receiving quandrantectomy alone vs those
also receiving quadrantectomy plus 5 weeks of EBRT was
23.5 versus 5.8 %, respectively, with the difference less in
older patients.
A multicenter randomized trial in women older than
55 years compared wide excision surgery alone (1 cm clear
margins) with wide excision surgery plus 5 weeks of
EBRT with an EBRT boost.17 Almost all patients received
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adjuvant hormonal therapy. With a median follow-up of
9 years, the local recurrence rates were 4.4 % for excision
alone versus 3.4 % for excision plus radiation therapy,
p = NS.
In TARGIT-A, the combination of surgical excision and
effective radiation treatment depth is less than in Milan III,
and in some cases, even less than 10 mm total. At
29 months median follow-up, the TARGIT-A postpathol-
ogy (all of whom received a single-dose treatment in a
second procedure) had local recurrence rates of 5.7 %,
whereas prepathology patients (21 % of whom also
received 5 weeks of WBI) had local recurrence rates of
2.1 %.
Fewer deaths were observed in the TARGIT arm than
the EBRT arm, 37 versus 51, p = 0.008 (Table 3). The
TARGIT authors assert that TARGIT treatment, while
resulting in higher local recurrence rates, leads to an
overall improvement in survival due to fewer non-breast
cancer deaths. This conclusion is one of the main findings
in the TARGIT-A update publication.7 The authors rec-
ommend that clinicians advise patients that while TARGIT
bears a higher risk of local recurrence, TARGIT may
decrease overall mortality by 2.3 %.
Harness et al. and Yarnold et al. argue that it is
impossible for the 12-year-old Targit study, with a median
follow-up of 29 months, to impact other cancer deaths,
since the latency period for inducing non-breast cancers
from breast treatment is known to be 15–20 years.18,19
Furthermore, deaths from stroke and ischemic bowel dis-
ease cannot be attributed to breast irradiation. If you
include only cardiac and breast cancer deaths, the differ-
ence between treatment arms is only two patients.
Significance in only achieved by including deaths that are
unrelated to radiation treatment.
Mackenzie et al., Yarnold et al., and Harness et al. argue
that Vaidya et al.’s assertion (fewer cardiac deaths from
TARGIT) is inconsistent with the Darby study, the very
study cited 1 in support of this claim.1,718–22 Mackenzie
et al. suggest differences in baseline cardiac risk factors in
the study groups are the most likely explanation for finding
more cardiac deaths in the EBRT arm.20 Vaidya et al.
concede that cardiovascular assessment was not recorded
prior to study entry, but speculates that IORT of the tumor
bed might have systemic beneficial effects that contribute
to reduction in non-breast cancer mortality.22 However,
this theory was not confirmed in the more mature ELIOT
study, which showed no differences in non-breast cancers
and overall survival, even out to 10 years of follow-up.23
TARGIT-A CONCLUSIONS
The TARGIT-A trial, like the ELIOT Trial, included
patients that today would not be considered the best choice
for APBI. TARGIT-A has contributed to our understanding
of whether a 1-day treatment may be possible, this time
using 50-kV X-rays. With 29 months of median follow-up,
the TARGIT Data are still immature and risk-adapted
IORT with 50-kV X-rays is still too early in follow-up to
select the subset of women whose local control will be
within their noninferiority criteria margin of 2.5 %. Pre-
pathology patients who meet the TARGIT-A inclusion
criteria appear to be the best candidates and, at this point,
show encouraging results. Until the data are more mature,
50-kV patients should be treated under strict institutional
protocols. When long-term results are available, it is likely
there will be a higher overall recurrence rate for TARGIT
when compared with EBRT, but, as with ELIOT, we may
be able to select subgroups of favorable patients where this
TABLE 3 Causes of death as reported in TARGIT-A update
All deaths Breast deaths and cardiac deaths, only




Targit postpath EBRT postpath
Breast cancer 20 16 20 (2.6 %) 16 (1.9 %) 17 (3.3 %) 15 (2.7 %) 3 (1.2 %) 1 (0.5 %)
Other cancers 8 16 p = 0.56 p = 0.72 p = 0.35
Cardiac death 2 8 2 8 NS NS NS NS
Strokes 0 2
Ischemic bowel 0 1
Other deaths 7 8
Total 37 51 22a 24a
Adapted from Table 2, Lancet7 w/Breast Cancer Deaths added
NS not stated
a Death due to breast cancer and cardiac events together
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difference is small and acceptable. How much additional
risk of local recurrence is acceptable will vary with patients
and the situation in which they find themselves.
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